Qiagen (NYSE:QGEN) Sees Large Volume Increase - Here's Why

Key Points

• Qiagen’s trading volume jumped 23% to approximately 3.1 million shares, while the stock fell to $42.695 from the prior close of $44.07.
• Analyst sentiment remains mixed, with a consensus rating of “Hold” and an average price target of $43.93; JPMorgan raised its target to $50, while Barclays and Stifel set targets at $40.
• Qiagen exceeded quarterly expectations, reporting $0.62 EPS versus the $0.60 estimate and $535.04 million in revenue. Institutional investors own about 70% of the company, with several firms increasing their positions.

Qiagen N.V. (NYSE:QGEN - Get Free Report) shares saw unusually-high trading volume on Monday . Approximately 3,107,377 shares changed hands during trading, an increase of 23% from the previous session's volume of 2,521,901 shares.The stock last traded at $42.6950 and had previously closed at $44.07.

Analysts Set New Price Targets

A number of research analysts have issued reports on the stock. Barclays set a $40.00 target price on shares of Qiagen and gave the company an "equal weight" rating in a report on Friday, August 7th. JPMorgan Chase & Co. upped their price target on Qiagen from $45.00 to $50.00 and gave the stock an "overweight" rating in a report on Friday, August 7th. Morgan Stanley raised Qiagen from an "overweight" rating to an "overweight" rating and raised their price objective for the company from $40.00 to $42.00 in a research note on Tuesday, June 23rd. Kepler Capital Markets set a $38.60 price objective on Qiagen and gave the stock a "hold" rating in a report on Thursday, June 25th. Finally, Stifel Nicolaus set a $40.00 target price on Qiagen in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and nine have assigned a Hold rating to the company's stock. According to MarketBeat.com, Qiagen presently has an average rating of "Hold" and a consensus price target of $43.93.

Qiagen Price Performance

The company has a debt-to-equity ratio of 0.48, a quick ratio of 2.31 and a current ratio of 2.85. The company's fifty day simple moving average is $40.75 and its two-hundred day simple moving average is $40.88. The stock has a market capitalization of $8.76 billion, a PE ratio of 21.83, a P/E/G ratio of 4.39 and a beta of 0.63.

Qiagen (NYSE:QGEN - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported $0.62 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.60 by $0.02. Qiagen had a net margin of 19.49% and a return on equity of 14.47%. The company had revenue of $535.04 million during the quarter, compared to analysts' expectations of $527.50 million. During the same quarter in the previous year, the business posted $0.60 earnings per share. The firm's quarterly revenue was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. As a group, sell-side analysts predict that Qiagen N.V. will post 2.43 EPS for the current year.

Institutional Investors Weigh In On Qiagen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. United Services Automobile Association purchased a new position in Qiagen during the first quarter worth $239,000. Prudential Financial Inc. lifted its position in shares of Qiagen by 74.9% in the second quarter. Prudential Financial Inc. now owns 8,873 shares of the company's stock valued at $426,000 after acquiring an additional 3,799 shares in the last quarter. Invesco Ltd. lifted its position in shares of Qiagen by 123.7% in the second quarter. Invesco Ltd. now owns 1,006,025 shares of the company's stock valued at $48,350,000 after acquiring an additional 556,387 shares in the last quarter. EverSource Wealth Advisors LLC boosted its stake in shares of Qiagen by 226.4% during the second quarter. EverSource Wealth Advisors LLC now owns 2,598 shares of the company's stock valued at $125,000 after acquiring an additional 1,802 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in shares of Qiagen during the second quarter valued at $3,639,000. Hedge funds and other institutional investors own 70.00% of the company's stock.

About Qiagen

Qiagen NV NYSE: QGEN is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company's solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company's product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source